Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › canagliflozin

canagliflozin

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of canagliflozin

17 trials tracked of canagliflozin: 14 in phase 3 or 4 and 7 with published results. The most-cited published study has 293 citations.

17Trials tracked
14Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 4 Phase 3 10 Phase 2 1 Other / NA 2
  1. Phase 3 Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes Completed · 293 cited
  2. Phase 4 Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents Completed · 142 cited
  3. Phase 3 Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin) Completed · 57 cited
  4. Phase 4 Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes Completed · 53 cited
  5. Phase 3 Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin) Completed · 31 cited
  6. Phase 3 Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy Completed · 28 cited
Show 11 more trials
  1. Phase 3 Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy Completed · 5 cited
  2. Phase 4 Mechanisms of Weight Loss With SGLT2 Inhibition Completed
  3. Phase 4 Treatment of Diabetes in Patients With Systolic Heart Failure Completed
  4. Phase 3 An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment Completed
  5. Phase 3 The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone) Completed
  6. Phase 3 The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial) Completed
  7. Phase 3 The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial Completed
  8. Phase 3 The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea) Completed
  9. Phase 2 Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants Completed
  10. N/A Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients Completed
  11. N/A Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
SGLT2 inhibitors reduce body fat without significant impacts on skeletal muscle mass in type 2 diabetes
Diabetes & Endocrinology Meta-analysis
SGLT2 inhibitors reduce body fat without significant impacts on skeletal muscle mass in type 2 diabetes SGLT2 Inhibitors Reduce Fat Mass in Type 2 Diabetes Patients
This network meta-analysis of 5,399 patients evaluated the effects of SGLT2 inhibitors on body composition. The study found that while SGLT2…
New analysis shows SGLT2 inhibitors consistently reduce body fat and weight in adults with type 2 diabetes without significantly reducing mu…
Frontiers Jul 29, 2026
Canagliflozin mitigates increased cardiovascular risk from low-normal sodium intake in type 2 diabetes and CKD
Cardiology RCT
Canagliflozin mitigates increased cardiovascular risk from low-normal sodium intake in type 2 diabetes and CKD Canagliflozin may protect hearts in patients with low sodium intake
This post hoc analysis of a randomized controlled trial involving 2573 participants with type 2 diabetes and chronic kidney disease found th…
A new analysis suggests the medication canagliflozin helps protect heart health in people with type 2 diabetes and kidney disease who eat le…
Jul 2, 2026
Network meta-analysis of finerenone and SGLT2 inhibitors in heart failure with preserved or mildly reduced ejection fraction
Drug Pipeline Meta-analysis
Network meta-analysis of finerenone and SGLT2 inhibitors in heart failure with preserved or mildly reduced ejection fraction New analysis shows finerenone and SGLT2 drugs help lower heart failure hospitalization risks for patients with preserved ejection fraction
This network meta-analysis evaluated finerenone, sodium–glucose cotransporter 2 inhibitors, renin–angiotensin system inhibitors, and angiote…
A large review of over 65,000 patients found that finerenone and SGLT2 inhibitors reduce hospital stays and worsening heart failure compared…
Frontiers May 15, 2026
Network meta-analysis compares bexagliflozin efficacy and safety with other SGLT2 inhibitors in type 2 diabetes
Diabetes & Endocrinology Meta-analysis
Network meta-analysis compares bexagliflozin efficacy and safety with other SGLT2 inhibitors in type 2 diabetes New analysis shows bexagliflozin helps lower blood sugar and weight in adults with type 2 diabetes compared to other drugs
This systematic review and network meta-analysis synthesized evidence on bexagliflozin versus other SGLT2 inhibitors and placebo in adults w…
A large review of 26,838 patients found bexagliflozin lowers blood sugar and weight well. It also lowers blood pressure and causes fewer inf…
Frontiers May 13, 2026
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
Diabetes & Endocrinology Meta-analysis
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes A Clear Winner Emerges for Diabetes Patients with Kidney Disease
This network meta-analysis evaluated novel antidiabetic drugs, including SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, i…
For millions managing both diabetes and kidney disease, new research clarifies which medications offer the best protection for their heart a…
Frontiers Apr 12, 2026